The diagnosis, biomarker identification and measurement of drug efficacy in mental illness and neurological conditions.

精神疾病和神经系统疾病的诊断、生物标志物识别和药物疗效测量。

• 批准号: nhmrc : 546242
• 负责人: Dr Caroline Gurvich
• 金额: $ 7.94万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/diagnosis-biomarker-identification-neurological-conditions/82068
• 关键词: diagnosis; biomarker; identification; measurement; drug

Globally, 2 billion people suffer from a neuropsychiatric illness. The cost is more than US$2 trillion a year. Hampering early intervention is the current lack of definitive, quantitative techniques for diagnosis and measurement of treatment efficacy. This research will determine whether the disease fingerprints produced by a new technique, EVestG, are diagnostically unique (to schizophrenia, depression and Parkinson's disease) and sensitive to disease progression and treatment response.

全球有20亿人患有神经精神疾病。每年的成本超过2万亿美元。阻碍早期干预的是目前缺乏明确的、定量的诊断和治疗效果测量技术。这项研究将确定由一项新技术EVestG产生的疾病指纹在诊断上是否独特（对精神分裂症、抑郁症和帕金森病），对疾病进展和治疗反应是否敏感。